A Role for PI 3-Kinase and PKB Activity in the G2/M Phase of the Cell Cycle  by Shtivelman, Emma et al.
Current Biology, Vol. 12, 919–924, June 4, 2002, 2002 Elsevier Science Ltd. All rights reserved. PII S0960-9822(02)00843-6
A Role for PI 3-Kinase and PKB Activity
in the G2/M Phase of the Cell Cycle
Inhibition of PI 3-Kinase Induces Apoptosis
in HeLa and MDCK Cells
We analyzed the effect of inhibiting PI 3-kinase on sur-
Emma Shtivelman,1 Joshua Sussman,
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Cancer Research Institute
University of California, San Francisco vival and cell cycle progression. Cells were collected at
different time points after the addition of LY294002, a PISan Francisco, California 94143-0128
3-kinase inhibitor, and were analyzed for DNA content. In
MDCK cells, the transition from G1 to S phase was fully
inhibited by 6–8 hr; however, a significant proportion ofSummary
cells arrested with a 4n amount of DNA, and some cells
succumbed to apoptotic death (Figure 2). Treatment ofThe role of the PI 3-kinase cascade in regulation of
HeLa cells with LY294002 also resulted in a cell subpop-cell growth is well established [1]. PKB (protein kinase
ulation with a 4n amount of DNA as well as accumulationB) is a key downstream effector of the PI 3-kinase
of apoptotic cells (Figure 2 and Table S1). NIH 3T3 cellspathway and is best known for its antiapoptotic effects
showed a slight delay in progression through G2/M but[2, 3] and the role it plays in initiation of S phase [4].
eventually arrested predominantly in the G1 phase (Fig-Here, we show that PKB activity is high in the G2/M
ure 2). About 20% of cells of glioblastoma U373 treatedphase of the cell cycle in epithelial cells. Inhibition
with LY294002 remained trapped with a 4n amount ofof the PI 3-kinase pathway in MDCK cells induces
DNA for at least 24 hr (see the Supplementary Material).apoptosis at the G2/M transition, prevents activation
of cyclin B-associated kinase, and prohibits entry of
the surviving cells into mitosis. All of these conse-
Inhibition of the PI 3-Kinase Pathway during Squences of the inhibition of PI 3-kinase are relieved
Phase Induces a G2 Arrest and Apoptosisby expression of a constitutively active form of PKB
of MDCK and HeLa Cells(caPKB), indicating that PKB plays a role in regulation
Because the majority of cells in asynchronous popula-of the G2/M phase. Inhibition of PI 3-kinase results in
tions are in G1 phase, the potential effects of the inhibi-activation of Chk1, whereas caPKB inhibits the ability
tion of PI 3-kinase in the later stages of the cell cycleof Chk1 to become activated in response to treatment
might be obscured by the well-known inhibition of thewith hydroxyurea. Preliminary data show that PKB
G1 to S transition. Therefore, we have synchronizedphosphorylates the Chk1 polypeptide in vitro on serine
MDCK cells by a double thymidine block and added280. These results not only implicate PKB activity in
LY294002 in the late S phase (at 2 hr after release).transition through the G2/M stage of the cell cycle,
Between 4 and 5 hr after release from the thymidinebut they also suggest the existence of crosstalk be-
block, when untreated cells accumulate in G2 and starttween the PI 3-kinase pathway and the key regulators
entering mitosis, we observed a massive apoptosis ofof the DNA damage checkpoint machinery.
MDCK cells and an accumulation of surviving cells with
a 4n amount of DNA (Figures 3A and 3B).
Results and Discussion To distinguish between G2 versus mitotic arrest, we
calculated mitotic indices of MDCK cells treated with
PKB Activity Is Highest in the G2/M Phase LY294002. The data clearly showed that treatment of
of the Cell Cycle in Epithelial Cells MDCK cells with LY294002 results in a G2 arrest (Figure
We have examined the kinase activity of PKB throughout 3B) and that apoptosis occurs as cells attempt to transit
the cell cycle in cells synchronized at the G1/S boundary from G2 to M phase.
by a double thymidine block (HeLa and MDCK) or in G1 The caspase inhibitor zVAD, but not unrelated prote-
phase by serum starvation (NIH 3T3). The activity of PKB ase inhibitor zFA, almost completely inhibited the ap-
in HeLa cells increases as cells enter G2 and progress pearance of cells with fragmented DNA when added
to mitosis and drops precipitously as cells complete simultaneously with LY294002, strongly indicating
mitosis and return to the G1 phase (Figure 1A). Results involvement of caspases and the apoptotic nature of cell
of the immune complex kinase assays correlate with the death. zVAD had no effect on the G2 arrest of LY294002-
levels of active PKB determined by Western blot analysis treated MDCK cells (see the Supplementary Material).
with phosphospecific antibodies to phosphoserine 473 Inhibition of PI 3-kinase in NIH 3T3 cells in late S phase
(Figure 1B). (Figure 3C) resulted in a delay in both the S phase and
Similar to HeLa cells, PKB activity in MDCK cells is mitotic progression, but not apoptosis (Figures 3C and
highest in the late G2/early M phase of the cell cycle 3D). Delay in mitotic progression paralleled the observed
(Figure 1); but, in NIH 3T3 cells, activity of PKB is not delay and decrease in activation of the mitotic cyclin
increased in G2/M (see the Supplementary Material B/cdk1 complex (see the Supplementary Material).
available with this article online). These results suggest a Treatment of synchronized HeLa cells with LY294002
possible role for PKB in mitotic progression in epithelial in the late S phase resulted in a significant reduction in
cells. the number of cells entering mitosis, delay of the mitotic
timing, and accumulation of apoptotic cells (Figure 3D).
About 20% of cells died while attempting to transit1Correspondence: shtivelman@cc.ucsf.edu
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Figure 1. PKB Activity Is Highest in the G2/M Phase of the Cell Cycle in Epithelial Cell Lines
(A) Quantitation of PKB activity in the in vitro kinase assay. Protein extracts were prepared with HeLa and MDCK cells synchronized by a
double thymidine block. Activity of endogenous PKB was determined in the immune complex in vitro kinase assay with Crosstide substrate
as described [5]. Incorporation of 32P into substrate was quantified using Phosphorimager. The numbers directly below the x axis indicate
hours after release from the double thymidine block. Percentages of cells with a 4n amount of DNA (G2/M) are shown below the hours after
release. Cell cycle progression was monitored by flow cytometric analysis of cellular DNA content in fixed propidium iodide-stained cells.
The data shown represent one out of two experiments that produced practically identical profiles of PKB activity.
(B) Western blot analysis of PKB phosphorylation on serine 473 and total PKB protein levels in synchronized cell lines. In each set, the upper
panel shows Western blots probed with the antibody specifically recognizing phosphorylated PKB (pSer473), and the lower panel shows the
same blot reprobed with the anti-pleckstrin homology domain antibody (PH-PKB). The numbers directly below the lower panel indicate time
in hours elapsed after release of cells from the double thymidine block (HeLa and MDCK). The percentages of cells in different phases of the
cell cycle are also shown. The mitotic indices were determined by examining the nuclear morphology of DAPI-stained cells.
through the G2/M phase, and about 20% of cells did MDCKneo and MDCK-caPKB clones were synchro-
nized and subjected to treatment with LY294002 in Snot progress from G2 to M (Figure 3E).
phase as described above. caPKB fully protected MDCK
from apoptosis during the G2/M phase of the cell cycleConstitutively Active PKB Prevents Apoptosis
(Figures 4B and 4C). Moreover, the MDCK-caPKB cellsand Promotes Mitotic Progression when
underwent only a delay in G2 and progressed throughPI 3-Kinase Signaling Is Inhibited
mitosis, as shown by the calculation of mitotic indicesNext, we examined if the G2 arrest and apoptosis re-
and specific staining of mitotic cells with the MPM2sulting from the inhibition of the PI 3-kinase pathway in
antibody [6] (Figures 4B and 4C).MDCK cells is at least partially a consequence of the
Cyclin B-associated kinase activity is inhibited ininhibition of PKB activity within this pathway. To address
MDCKneo cells treated with LY294002 compared to un-this possibility, a form of PKB that is unresponsive to
treated cultures progressing through G2/M (Figure 4D).phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3)
In MDCK-caPKB cells treated with LY294002, mitoticsignaling and therefore resistant to treatment with
kinase is active at 8 and 10 hr after release, correspond-LY294002 was introduced into MDCK cells. This consti-
ing to the increase in mitotic indices and MPM2 positivitytutively active PKB (caPKB) lacks the pleckstrin homol-
(Figures 4C and 4D). These data indicate that PKB activ-ogy domain, and, to ensure the constitutive activity of
ity might be necessary for activation of mitotic kinasethis enzyme in the absence of membrane targeting, two
and progression from G2 to mitosis in MDCK cells.residues that are phosphorylated in activated PKB, ser-
ine 473 and threonine 308, were changed to aspartic
acid [5]. Exogenous caPKB introduced into MDCK cells Inhibition of the PI 3-Kinase/PKB Pathway
in Epithelial Cells Is Associated withshowed a very high activity toward a peptide substrate
in vitro (Figure 4A). Importantly, while endogenous PKB, an Increase in Kinase Activity of Chk1
In search of potential substrates of PKB that might beas expected, was inhibited by treatment with LY294002,
the caPKB remained active (Figure 4A). relevant to the G2 arrest resulting from PI 3-kinase inhibi-
Brief Communication
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Figure 2. Inhibition of the PI 3-Kinase Pathway Results in Delay/Arrest with a 4n Amount of DNA
Asynchronously growing cell lines were harvested at different times after the addition of 30 M LY294002. The percentage of cells in different
stages of the cell cycle and of apoptotic cells was quantified by flow cytometric analysis of DNA content in fixed cells stained with propidium
iodide.
tion, we have identified a conserved potential PKB phos- throughout the cell cycle in HeLa and MDCK cells. In
both lines, the levels of PtdIns(3,4,5)P3 did not changephorylation site at serine 280 of the human Chk1 kinase
sequence [7]. This residue is phosphorylated by PKB in significantly as cells progressed through S and G2/M
phases (data not shown). Therefore, changes in totalvitro (see the Supplementary Material).
We examined if inhibition of PI 3-kinase and the pres- PtdIns(3,4,5)P3 levels are not likely to explain changes
in PKB activity, and other mechanisms such as regula-ence of caPKB affect the basal activity or hydroxyurea-
induced activity of Chk1. In addition to MDCK clones, tion of PKB activity by phosphatases [9] might be in-
volved.we have derived stable clones of breast carcinoma
line MCF7 expressing caPKB. Although the activity of Our results implicate Chk1 as a potential G2/M target
of the PI 3-kinase/PKB pathway. In vitro phosphorylationexogenous caPKB in MCF7 clones was much lower than
in MDCK, it was also resistant to treatment with of Chk1 by PKB suggests that PKB directly phosphory-
LY294002 (data not shown). Treatment of MCF7 and lates Chk1 in vivo and regulates its activity. This possibil-
MDCK control clones with LY294002 resulted in a signifi- ity is supported by the data demonstrating the inhibition
cant increase in the kinase activity of Chk1 (Figure 4E). of Chk1 activation by caPKB in vivo. Inappropriate acti-
These results indicate that inhibition of the PI 3-kinase vation of Chk1 as a consequence of the PI 3-kinase/PKB
results in activation of Chk1 in the absence of hydroxy- inhibition might contribute to the observed G2 arrest,
urea. However, treatment of caPKB-expressing clones because Chk1 is involved in the regulation of the G2/M
of MCF and MDCK cells with LY294002 or hydroxyurea transition [10]. However, we have no evidence that
failed to elicit an increase in Chk1 activity (Figure 4E). caPKB inhibits the basal activity of Chk1 kinase in cells
This indicates that inhibition of PKB is a culprit in the not subjected to DNA damage. We suggest that PKB
activation of Chk1 by inhibition of the PI 3-kinase path- inhibits Chk1 activation in response to DNA damage.
way or in response to stalled DNA replication by hy- The inhibitory effect of inappropriately active PKB on
droxyurea. Chk1 kinase might have important implications for
In conclusion, we have found an unanticipated role understanding how tumor cells with deregulated PI
for the PI 3-kinase signal transduction pathway and PKB 3-kinase pathways respond to DNA damage. At least
in regulation of the G2/M transition. PKB activity pro- one report indicates a role for the PI 3-kinase/PKB sig-
tects MDCK cells from apoptosis during the G2/M transi- naling in overriding DNA damage-induced G2 arrest [11].
tion and is necessary for activation of the mitotic kinase. Our preliminary results support these observations. It
High activity of PKB in G2/M appears to be a specific remains to be determined whether other regulators of
feature of cell cycle progression in epithelial cells, al- the G2/M transition are targets of PI 3-kinase/PKB path-
though the limited number of cell lines analyzed in this way. In this respect, a recent report showing a role for
study does not allow us to make generalizations about PKB in reinitiating meiosis in starfish oocytes through
our findings. It is possible that epithelial cells entering inhibitory phosphorylation of Myt1 kinase [12] is of par-
mitosis need additional antiapoptotic mechanisms in ticular interest.
view of their susceptibility to anoikis [8], which might
be triggered by the partial loss of cell-cell and cell-
Supplementary Materialsubstrate adherence during mitosis. PKB might provide
Supplementary Material including tables with numerical values forprotection against this. Indeed, MDCK cells entering
cell cycle data in Figures 2 and 3, data on inhibition of apoptosismitosis in suspension are temporarily protected by
in LY294002-treated cells by zVAD, as well as figures showing PKB
caPKB from anoikis (data not shown). activity in NIH 3T3 cells, the effect of LY294002 on cyclin B/cdk1
We have addressed the potential mechanism of PKB activity in NIH 3T3 cells, and in vitro phosphorylation of Chk1 by PKB
is available at http://images.cellpress.com/supmat/supmatin.htm.activation in G2/M by analyzing levels of PtdIns(3,4,5)P3
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Figure 3. Inhibition of PI 3-Kinase in Late S Phase Induces a G2 Arrest/Delay and Apoptosis
(A) Flow cytometric analysis of DNA content in MDCK cells synchronized by a double thymidine block at G1/S phase and released into full
medium. Parallel cultures were treated with 30 M LY294002 added 2 hr after release. Cells were processed for analysis of DNA content by
flow cytometry of PI-stained cells and for determination of mitotic indices in DAPI-stained cytospin preparations (at least 400 cells were
counted for each time point).
(B) Cell cycle progression and apoptosis in MDCK cultures treated as in (A). The percentages of cells with a 4n amount of DNA (G2/M), mitotic
cells (mit), and cells with less than a 2n amount of DNA (apo) are shown. Control cultures are shown in the top panel, and cultures treated
with 30 M LY294002 added 2 hr after release are shown in the bottom panel. Apoptotic cells in the untreated cultures did not exceed 1%–2%
of total at any time.
(C) NIH 3T3 cells were synchronized by serum starvation for 24 hr and were released into full medium. Treatment of parallel cultures with 50
M LY294002 was initiated 13 hr after release.
(D) Progression through G2/M phase in NIH 3T3 cultures treated as described in (C). UT, untreated cultures; LY, cultures treated with LY29402.
(E) Cell cycle progression in double thymidine block-synchronized HeLa cells with or without treatment with LY294002 (30 M, added 3 hr
after release, right panel). The percentages of cells with a 4n amount of DNA (G2/M) and a 2n amount of DNA (apo) were calculated from
flow cytometric analysis of DNA content. The arrowheads below the x axis indicate times of the addition of LY294002.
Figure 4. caPKB Is Active in the Presence of LY294002 and Protects MDCK Cells from Apoptosis and G2 Arrest
(A) Activity of PKB in MDCKneo (control) and MDCK-caPKB clones treated with LY294002. Cells were synchronized, treated with LY294002
as described in Figure 3, and harvested at 5 hr after release. PKB (endogenous and exogenous) was precipitated with anti-PKB antibodies
and anti-epitope tag antibodies against the Glu-Glu epitope tag on caPKB, respectively. Kinase activity was measured as described in the
legend of Figure 1. White bars represent MDCKneo cells, and black bars represent MDCK-caPKB cells.
(B) CaPKB protects MDCK from apoptosis and relieves G2 arrest. MDCKneo and caPKB clones were synchronized by a double thymidine
block, released into fresh medium, and treated with LY294002 1.5 hr after release. DNA content was analyzed by flow cytometry.
(C) Cell cycle progression and apoptosis in MDCKneo and MDCK-caPKB clones treated with LY294002 as in (B). Percentages of apoptotic
(Apo), mitotic (Mit), and MPM2-positive (MPM2) cells are shown.
(D) Cyclin B1-associated kinase activity is inhibited in synchronized MDCK cells treated with LY294002 but is restored in cells expressing
caPKB. Lysates prepared from synchronized MDCKneo (white bars) and caPKB cells (black bars) were analyzed for kinase activity precipitated
using anti-cyclin B1 antibodies. Histone H1 was used as a substrate in the immune complex-linked in vitro kinase assay. The numbers directly
below the x axis indicate hours after release from thymidine block with or without the addition of LY294002 at 1.5 hr. Data are presented as
the fold increase of HH1 kinase activity over that precipitated from double thymidine-arrested cells (time point 0) and are the average of three
experiments performed.
(E) Activity of endogenous Chk1 was assayed in the immune complex kinase assay with GSTcdc25(200-256) as a substrate as described [13].
Cells were either untreated (UT), treated with 30 M LY294002 for 3 hr (LY), or treated with 2 mM hydroxyurea (HU) for 16 hr (MCF7) or 5 hr
(MDCK). Results are expressed relative to the values observed in extracts from untreated cells and are an average of three experiments
performed.
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